Sun Pharma-ranbaxy Merger
- All
- News
-
Sun Pharma To Release Salary To Ex-Ranbaxy Representatives Using Company App
As part of the integration of erstwhile Ranbaxy, it was decided to use Target Application as a single platform for DAR for the India field force, Sun Pharma said.
-
Will Release Salary To Ex-Ranbaxy Representatives If They Use Company App: Sun Pharma
As part of the integration of erstwhile Ranbaxy, it was decided to use Target Application as a single platform for DAR for the India field force, Sun Pharma added.
-
Ranbaxy Integration: Sun Pharma May Drop Some Non-Strategic Units
Currently, all the four manufacturing facilities of Ranbaxy - Mohali and Toansa in Punjab, Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh - have been banned by the USFDA from export of drugs to the US market.
-
Sun Pharma Expects Ranbaxy Costs to Hit FY16 Revenue
Sun Pharmaceutical Industries Ltd, India's largest drug maker, said on Monday that its revenue in fiscal year 2016 would be flat at best as it struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.
-
Sun Pharma to Delist Ranbaxy on Completion of $4 Billion Merger
Ranbaxy has been facing issues raised by the FDA, US authorities and health regulators in the European markets.
-
Sun Pharma Open to Large Acquisitions Post-Ranbaxy Deal
Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, said on Wednesday that its $3.2-billion (Rs 19,840 crore at 1 dollar = 62 rupees) acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.
-
Sun Pharma Expects Ranbaxy Deal to be Closed by February
Recently in a joint statement, the two firms had said that they have received the CCI order where acquisition of Ranbaxy by Sun Pharma has been approved "subject to compliance with certain conditions".
-
Fair Trade Regulator's Decision on Sun Pharma-Ranbaxy Deal This Month: Report
The Competition Commission of India (CCI) is likely to finalse this month its decision on the $4-billion Sun Pharma-Ranbaxy deal - the first M&A (merger and acquisition) transaction to have gone through public scrutiny amid concerns of its adverse impact on fair competition in the market.
-
Sun Pharma-Ranbaxy merger: High Court to Hear Plea on Saturday
After hearing the arguments from the counsels of the petitioners, Ranbaxy, Sun Pharma and SEBI, Justice G Chandraiah said he will pronounce the verdict tomorrow.
-
Sun Pharma, Ranbaxy shares drop as merger put on hold
Ranbaxy shares fell as much as 3.7 per cent in early trade on Wednesday, while shares in Sun Pharma fell as much as 2.7 per cent on the back of the decision from Andhra Pradesh High Court to maintain interim status quo on the Sun Pharma-Ranbaxy merger process.
-
Sun Pharma-Ranbaxy merger put on hold by Andhra Pradesh High Court
According to legal experts, both Sun Pharma and Ranbaxy will have to obtain approvals from BSE and NSE before proceeding for further clearances from various institutions such as Competition Commission of India and respective High Courts, on the merger.
-
Maintain status-quo on Sun Pharma-Ranbaxy merger: Court to BSE, NSE
The petitioners alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6, and requested the court to direct the SEBI to investigate the insider trading of Ranbaxy shares and take appropriate action against Sun Pharma and Silver Street.
-
Ranbaxy's journey as a company to end after merger with Sun Pharma
Sun Pharma said on April 7 it would fully acquire Ranbaxy, which was incorporated in 1961 and went public in 1973. It will offer 0.8 share of Sun Pharma for each Ranbaxy share, representing an implied value of Rs 457 per Ranbaxy share.
-
Sun Pharma To Release Salary To Ex-Ranbaxy Representatives Using Company App
As part of the integration of erstwhile Ranbaxy, it was decided to use Target Application as a single platform for DAR for the India field force, Sun Pharma said.
-
Will Release Salary To Ex-Ranbaxy Representatives If They Use Company App: Sun Pharma
As part of the integration of erstwhile Ranbaxy, it was decided to use Target Application as a single platform for DAR for the India field force, Sun Pharma added.
-
Ranbaxy Integration: Sun Pharma May Drop Some Non-Strategic Units
Currently, all the four manufacturing facilities of Ranbaxy - Mohali and Toansa in Punjab, Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh - have been banned by the USFDA from export of drugs to the US market.
-
Sun Pharma Expects Ranbaxy Costs to Hit FY16 Revenue
Sun Pharmaceutical Industries Ltd, India's largest drug maker, said on Monday that its revenue in fiscal year 2016 would be flat at best as it struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.
-
Sun Pharma to Delist Ranbaxy on Completion of $4 Billion Merger
Ranbaxy has been facing issues raised by the FDA, US authorities and health regulators in the European markets.
-
Sun Pharma Open to Large Acquisitions Post-Ranbaxy Deal
Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, said on Wednesday that its $3.2-billion (Rs 19,840 crore at 1 dollar = 62 rupees) acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.
-
Sun Pharma Expects Ranbaxy Deal to be Closed by February
Recently in a joint statement, the two firms had said that they have received the CCI order where acquisition of Ranbaxy by Sun Pharma has been approved "subject to compliance with certain conditions".
-
Fair Trade Regulator's Decision on Sun Pharma-Ranbaxy Deal This Month: Report
The Competition Commission of India (CCI) is likely to finalse this month its decision on the $4-billion Sun Pharma-Ranbaxy deal - the first M&A (merger and acquisition) transaction to have gone through public scrutiny amid concerns of its adverse impact on fair competition in the market.
-
Sun Pharma-Ranbaxy merger: High Court to Hear Plea on Saturday
After hearing the arguments from the counsels of the petitioners, Ranbaxy, Sun Pharma and SEBI, Justice G Chandraiah said he will pronounce the verdict tomorrow.
-
Sun Pharma, Ranbaxy shares drop as merger put on hold
Ranbaxy shares fell as much as 3.7 per cent in early trade on Wednesday, while shares in Sun Pharma fell as much as 2.7 per cent on the back of the decision from Andhra Pradesh High Court to maintain interim status quo on the Sun Pharma-Ranbaxy merger process.
-
Sun Pharma-Ranbaxy merger put on hold by Andhra Pradesh High Court
According to legal experts, both Sun Pharma and Ranbaxy will have to obtain approvals from BSE and NSE before proceeding for further clearances from various institutions such as Competition Commission of India and respective High Courts, on the merger.
-
Maintain status-quo on Sun Pharma-Ranbaxy merger: Court to BSE, NSE
The petitioners alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6, and requested the court to direct the SEBI to investigate the insider trading of Ranbaxy shares and take appropriate action against Sun Pharma and Silver Street.
-
Ranbaxy's journey as a company to end after merger with Sun Pharma
Sun Pharma said on April 7 it would fully acquire Ranbaxy, which was incorporated in 1961 and went public in 1973. It will offer 0.8 share of Sun Pharma for each Ranbaxy share, representing an implied value of Rs 457 per Ranbaxy share.
